Document Detail

High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.
MedLine Citation:
PMID:  17477827     Owner:  NLM     Status:  MEDLINE    
The ability of human immunodeficiency virus type 1 (HIV-1) to persist in a latent stage in memory T cells in the presence of antiretroviral therapy poses a major obstacle to the development of an HIV-1 therapy with curative intent. As latently infected cells are phenotypically not distinguishable from uninfected cells, therapeutic reactivation of the latent infection, followed by the death of the host cell induced by viral cytopathicity, is considered the only means to eliminate this viral reservoir. To identify compounds with the potential to reactivate latent HIV-1, we have developed a series of latently HIV-1-infected reporter cell lines that allow for high throughput drug screening (HTS) in a 384-well plate-based format. The latent reporter cell lines use enhanced green fluorescence protein (eGFP) as a direct and quantitative marker of HIV-1 expression. To aid identification of specific compounds, the cells are engineered to constitutively express a second, red fluorescent protein that has no spectral overlap with eGFP, which allows for the simultaneous quantification of cell viability (inversely correlated to compound toxicity). Thus, these reporters enable prioritization of compounds most likely to have a favorable therapeutic window. The high dynamic signal range and the excellent reproducibility of the primary screening assay result in a Z' -factor of 0.89, which characterizes the HTS system as very robust. The assay has been implemented for automated drug screening, and we here discuss the advantages and limitations of the HTS system based on the data obtained for 1,600 compounds during a limited proof-of-concept drug screen.
Jennifer Jones; John Rodgers; Marintha Heil; Jori May; Lucile White; Joseph A Maddry; Thomas M Fletcher; George M Shaw; John L Hartman; Olaf Kutsch
Related Documents :
16005307 - Monte carlo estimates of natural variation in hiv infection.
14657387 - Viral protein u counteracts a human host cell restriction that inhibits hiv-1 particle ...
17477827 - High throughput drug screening for human immunodeficiency virus type 1 reactivating com...
20151187 - Over-expression of the hiv-1 rev promotes death of nondividing eukaryotic cells.
9349497 - Oncogenic transformation potentiates apoptosis, s-phase arrest and stress-kinase activa...
25124757 - Cell-intrinsic timing in animal development.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Assay and drug development technologies     Volume:  5     ISSN:  1540-658X     ISO Abbreviation:  Assay Drug Dev Technol     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-05-04     Completed Date:  2007-06-06     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  101151468     Medline TA:  Assay Drug Dev Technol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  181-89     Citation Subset:  IM    
Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / pharmacology*
Cell Line
Drug Evaluation, Preclinical
Genes, Reporter / genetics
Genetic Markers
Green Fluorescent Proteins / genetics
HIV Core Protein p24 / biosynthesis,  genetics
HIV-1 / drug effects*
Indicators and Reagents
Plasmids / genetics
Transduction, Genetic
Virus Replication / drug effects
Grant Support
Reg. No./Substance:
0/Anti-HIV Agents; 0/Genetic Markers; 0/HIV Core Protein p24; 0/Indicators and Reagents; 147336-22-9/Green Fluorescent Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Applications of RNA interference in mammalian systems.
Next Document:  Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels usin...